Form 8-K - Current report:
SEC Accession No. 0001737287-20-000045
Filing Date
2020-08-05
Accepted
2020-08-05 07:36:27
Documents
16
Period of Report
2020-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K allo-20200805.htm   iXBRL 8-K 43254
2 EX-99.1 allo-20200630xexx991q2.htm EX-99.1 106463
8 g725933allogenea061.jpg GRAPHIC 7772
  Complete submission text file 0001737287-20-000045.txt   314870

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT allo-20200805.xsd EX-101.SCH 2508
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT allo-20200805_cal.xml EX-101.CAL 795
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT allo-20200805_def.xml EX-101.DEF 1759
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT allo-20200805_lab.xml EX-101.LAB 24275
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT allo-20200805_pre.xml EX-101.PRE 12731
9 EXTRACTED XBRL INSTANCE DOCUMENT allo-20200805_htm.xml XML 10938
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Filer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38693 | Film No.: 201075650
SIC: 2836 Biological Products, (No Diagnostic Substances)